Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice

Acta Neuropathologica

Volumn 120, Issue 2, 2010, Pages 145-154

  Tanji, Kunikazu ^a   Mori, Fumiaki ^a   Mimura, Junsei ^b   Itoh, Ken ^b   Kakita, Akiyoshi ^c   Takahashi, Hitoshi ^c   Wakabayashi, Koichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

synuclein; Dementia with lewy bodies; Parkinson's disease; Presynapse; Proteinase k; Transgenic mice

Indexed keywords

ADENINE; ALPHA SYNUCLEIN; MUTANT PROTEIN; PROTEINASE K; THYMINE; SNCA PROTEIN, MOUSE; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL FRACTIONATION; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; EMBRYO; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NEURITE; NEUROTRANSMISSION; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SUBSTANTIA NIGRA; SYNAPTOSOME; TEMPORAL CORTEX; TRANSGENIC MOUSE; ANIMAL; BRAIN; CADAVER; CASE CONTROL STUDY; CELL LINE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; LEWY BODY; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CASE-CONTROL STUDIES; CELL LINE, TRANSFORMED; ENDOPEPTIDASE K; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; MUTATION; POSTMORTEM CHANGES; PRESYNAPTIC TERMINALS; SYNAPTOPHYSIN; TRANSFECTION;

EID: 77957266699     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0676-z     Document Type: Article

References (41)

1. Abeliovich A, Schmitz Y, Farinas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25: 239-252
2. Beach TG, White CL, Hamilton RL et al (2008) Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 116: 277-288
3. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211
4. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. J Neuropathol Exp Neurol 24: 398-414
5. Fernagut PO, Hutson CB, Fleming SM et al (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 61:991-1001
6. Fujiwara H, Hasegawa M, Dohmae N et al (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164
7. Galvin JE, Uryu K, Lee VM, Trojanowski JQ (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA 96: 13450-13455
8. Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989
9. Giasson BI, Duda JE, Quinn SM et al (2002) Neuronal alphasynucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533
10. Hasegawa M, Fujiwara H, Nonaka T et al (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277: 49071-49076
11. Iwai A, Masliah E, Yoshimoto M et al (1995) The precursor protein of non-Abeta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475
12. Iwatsubo T, Yamaguchi H, Fujimuro M et al (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol. 148: 1517-1529
13. Jakes R, Crowther RA, Lee VM et al (1999) Epitope mapping of LB509, a monoclonal antibody directed against human alphasynuclein. Neurosci Lett 269: 13-16
14. Kahle PJ (2008) Alpha-synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 115: 87-95
15. Kahle PJ, Neumann M, Ozmen L et al (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20: 6365-6373
16. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alphasynuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 27: 1405-1410
17. Kmger R, Kuhn W, Muller T et al (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108
18. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 75: 345-353
19. Lee MK, Stirling W, Xu Y et al (2002) Human alpha-synucleinharboring familial Parkinson's disease-linked Ala-53-→ Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99: 8968-8973
20. Liu S, Ninan I, Antonova I et al (2004) Alpha-synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 23:4506-4516
21. Lu XH, Fleming SM, Meurers B et al (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 29:1962-1976
22. Maroteaux L, Scheller RH (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res 11: 335-343
23. Masliah E, Rockenstein E, Veinbergs I et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269
24. Matsuoka Y, Vila M, Lincoln S et al (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8: 535-539
25. Mori F, Piao YS, Hayashi S et al (2003) Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. J Neuropathol Exp Neurol 62: 812-819
26. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176: 98-104
27. Neumann M, Kahle PJ, Giasson BI et al (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110: 1429-1439
28. Neumann M, Muller V, Kretzschmar HA, Haass C, Kahle PJ (2004) Regional distribution of proteinase K-resistant alphasynuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol. 63: 1225-1235
29. Piao YS, Mori F, Hayashi S et al (2003) Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha- synucleinopathies. Acta Neuropathol 105: 403-409
30. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
31. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA et al (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175:35-48
32. Rockenstein E, Mallory M, Hashimoto M et al (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy1 promoters. J Neurosci Res 68: 568-578
33. Takeda A, Hashimoto M, Mallory M et al (2000) C-terminal alphasynuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol 99: 296-304
34. Takeda A, Hashimoto M, Mallory M et al (1998) Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 78: 1169-1177
35. Tanji K, Tanaka T, Mori F et al (2006) NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1. Am J Pathol 169: 553-565
36. van der Putten H, Wiederhold KH, Probst A et al (2000) Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20: 6021-6029
37. Wakabayashi. K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180-182
38. Yavich L, Oksman M, Tanila H et al (2005) Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 20: 303-313
39. Yavich L, Tanila H, Vepsalainen S, Jakala P (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci. 24: 11165-11170
40. Zarranz JJ, Alegre J, Gomez-Esteban JC et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173
41. Zhang HX, Tanji K, Mori F, Wakabayashi K (2008) Epitope mapping of 2E2-D3, a monoclonal antibody directed against human TDP-43. Neurosci Lett 434: 170-174